Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib in Pancreatic Cancer (Phase 2, Single-Arm)
ChiCTR2200058787Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluzoparib in pancreatic cancer (PC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
fluzoparib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2200058787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058787.